Cargando…
Gap Junction Enhancer Increases Efficacy of Cisplatin to Attenuate Mammary Tumor Growth
Cisplatin treatment has an overall 19% response rate in animal models with malignant tumors. Increasing gap junction activity in tumor cells provides the targets to enhance antineoplastic therapies. Previously, a new class of substituted quinolines (PQs) acts as gap junction enhancer, ability to inc...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441663/ https://www.ncbi.nlm.nih.gov/pubmed/23028705 http://dx.doi.org/10.1371/journal.pone.0044963 |